Slide 1: Simplifying Progress – Investor Conference Call H1 2025 Results
Simplifying Progress Investor Conference Call H1 2025 Results Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | July 22, 2025
Slide 2: H1 2025 shows expected strong recovery in recurring business
Sartorius Group H1 2025 shows expected strong recovery in recurring business ▪ Robust sales growth of 6% cc; significant ul EBITDA margin expansion to ~30% ▪ Bioprocess Solutions: Sales revenue strongly up driven by high-margin consumables business; industry-wide reluctance to invest continues to af
Slide 3: Agenda
Agenda Sartorius Group H1 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group H1 2025 results | FY 2025 outlook Questions & Answers 3
Slide 4: Robust sales revenue growth and substantial increase in profitability
Sartorius Group Robust sales revenue growth and substantial increase in profitability Sartorius Group H1 2024 H1 2025 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 1,680 1,767 +5.2 +6.1 Underlying EBITDA2 471 527 +11.9 Underlying EBITDA2 margin in % 28.1 29.8 +1.7pp Underl
Slide 5: Solid growth momentum across all regions
Sartorius Group Solid growth momentum across all regions EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +5.9% +7.1% +5.0% EMEA Americas 691 732 603 638 ~41% ~36% 387 397 €1,767m Asia | Pacific H1 2024 H1 2025 H1 2024 H1 2025 H1 202
Slide 6: Bioprocess Solutions: Significant growth and margin expansion
Sartorius Group Bioprocess Solutions: Significant growth and margin expansion Sales revenue +8.8% cc Ul EBITDA & margin € in millions +7.8% € in millions +16.5% 1,435 1,331 500 453 55 450 389 50 400 45 350 300 40 250 29.2 31.6 35 200 30 150 25 100 50 20 0 15 H1 2024 H1 2025 H1 2024 H1 2025 ▪ Strong
Slide 7: Lab Products & Services: Soft end markets weigh on performance
Sartorius Group Lab Products & Services: Soft end markets weigh on performance Sales revenue Ul EBITDA & margin -4.0% cc € in millions € in millions -4.8% -10.1% 349 82 332 74 23.6 22.3 H1 2024 H1 2025 H1 2024 H1 2025 ▪ Instruments business impacted by muted investment activity of customers, particu
Slide 8: Substantial increase in net profit and solid free cash flow generation
Sartorius Group Substantial increase in net profit and solid free cash flow generation Sartorius Group H1 2024 H1 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 148 169 +13.7 ▪ Operating cash flow on solid level; growth-driven Reported net profit2 61 81 +33.0 increase
Slide 9: Deleveraging on track; commitment to investment-grade rating
Sartorius Group Deleveraging on track; commitment to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Jun. 30, 5,000 5.0 in millions of € unless otherwise specified 2024 2025 4,000 4.0 Equity ratio in % 38.6 37.8 3,000 3.0 2,000
Slide 10: 2025 guidance confirmed
Sartorius Group 2025 guidance confirmed Guidance 2025 Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue growth1 + ~6% (+/- 2pp) + ~7% (+/- 2pp) + ~1% (+/- 2pp) Underlying EBITDA margin ~29% to ~30% ~31% to ~32% ~22% to ~23% ▪ Capex ratio of around 12.5% For financial modelli
Slide 11: Agenda
Agenda Sartorius Group H1 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group H1 2025 results | FY 2025 outlook Questions & Answers 11
Slide 12: Robust sales revenue growth and substantial increase in profitability
Sartorius Stedim Biotech Group Robust sales revenue growth and substantial increase in profitability Sartorius Stedim Biotech Group H1 2024 H1 2025 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 1,373 1,490 +8.5 +9.4 Underlying EBITDA2 387 462 +19.3 Underlying EBITDA2 margi
Slide 13: Solid growth momentum across all regions
Sartorius Stedim Biotech Group Solid growth momentum across all regions EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +8.7% +11.0% +8.1% EMEA Americas 575 625 ~42% ~36% 492 541 306 323 €1,490m Asia | Pacific H1 2024 H1 2025 H1 202
Slide 14: Substantial increase in net profit and solid free cash flow generation
Sartorius Stedim Biotech Group Substantial increase in net profit and solid free cash flow generation Sartorius Stedim Biotech Group H1 2024 H1 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 165 228 +38.3 ▪ Operating cash flow on solid level; growth-driven Reported ne
Slide 15: Deleveraging on track
Sartorius Stedim Biotech Group Deleveraging on track Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, June 30, 5.0 3,000 Group 2024 2025 4.0 in millions of € unless otherwise specified 2,000 3.0 Equity ratio in % 48.7 48.6 2.0 1,000 1.0
Slide 16: 2025 guidance confirmed
Sartorius Stedim Biotech Group 2025 guidance confirmed Guidance 2025 Sales revenue growth1 Underlying EBITDA margin Sartorius Stedim Biotech Group + ~7% (+/- 2pp) ~30% to ~31% ▪ Capex ratio of around 13% For financial modelling: Sartorius Stedim Biotech ▪ Net debt/ul. EBITDA to decrease to approx. 2
Slide 17: Questions & Answers
17 Questions & Answers RTORILS
Slide 18: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha